Loading...
Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults
OBJECTIVE: A recent study raises concerns that dipeptidyl peptidase 4 inhibitors (DPP4i) are associated with increased risk of inflammatory bowel disease (IBD). We evaluated the association between new use of DPP4i and IBD risk compared with other second-line antihyperglycemics. RESEARCH DESIGN AND...
Na minha lista:
| Udgivet i: | Diabetes Care |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Diabetes Association
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6804610/ https://ncbi.nlm.nih.gov/pubmed/31471377 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc19-0162 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|